

Supplemental Online Content

Chen T-L, Lee L-L, Huang H-K, Chen L-Y, Loh C-H, Chi C-C. Association of risk of venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors: a systematic review and meta-analysis. *JAMA Dermatol*. Published online August 24, 2022.
doi:10.1001/jamadermatol.2022.3516

eTable. Search Strategies for (a) MEDLINE, (b) Embase, (c) Cochrane Library, and (d) Web of Science

eFigure 1. Risk Differences in Venous Thromboembolism Between Participants With Atopic Dermatitis Receiving Janus Kinase Inhibitors and Controls Receiving Placebo or Dupilumab

eFigure 2. Funnel Plot of Randomized Controlled Trials

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable. Search Strategies for (a) MEDLINE, (b) Embase, (c) Cochrane Library, and (d) Web of science.

a. Search strategy for MEDLINE

#	Search syntax
1	("atopic dermatitis" or eczema*).mp.
2	exp "Dermatitis, Atopic"/ or exp "Eczema"/
3	(Venous adj2 thromboemboli\$).mp.
4	(VTE or DVT or PE).ti,ab,kw.
5	exp "Venous Thromboembolism"/ or exp "Pulmonary Embolism"/ or exp "Embolism"/ or exp "Deep Vein Thrombosis"/
6	((Janus adj3 kinase* adj3 inhibit*) or (JAK* adj3 inhibit*) or Abrocitinib or "PF-04965842" or Baricitinib or LY3009104 or Olumiant or INCB028050 or Gusacitinib or ASN002 or Tofacitinib or Tasocitinib or "Tofacitinib citrate" or Xeljanz or CP690550 or Upadacitinib or "ABT-494" or RINVOQ or Cerdulatinib or "RVT-502" or PRT062070 or Peficitinib or ASP015K or Filgotinib or GLPG0634 or Solcitinib or "1206163-45-2" or GLPG0778 or GSK2586184 or SHR0302 or "ATI-502" or "ATI 50002" or "A 301" or "PF-06700841" or "RVT-501" or Decernotinib or "VX-509" or Pacritinib or SB1518 or Fedratinib or TG101348 or SAR302503 or "Fedratinib hydrochloride" or Inrebic).mp.
7	exp "Janus Kinase Inhibitors"/
8	(#1 OR #2) AND (#3 OR #4 OR #5)
9	(#1 OR #2) AND (#6 OR #7)

b. Search strategy for Embase

#	Search syntax
1	("atopic dermatitis" or eczema*).mp.
2	exp "atopic dermatitis"/ or exp "eczema"/
3	(venous adj2 thromboemboli\$).mp.
4	(VTE or DVT or PE).ti,ab,kw.
5	exp "Venous Thromboembolism"/ or exp "Pulmonary Embolism"/ or exp "Embolism"/ or exp "Deep Vein Thrombosis"/
6	((Janus adj3 kinase* adj3 inhibit*) or (JAK* adj3 inhibit*) or Abrocitinib or "PF-04965842" or Baricitinib or LY3009104 or Olumiant or INCB028050 or Gusacitinib or ASN002 or Tofacitinib or Tasocitinib or "Tofacitinib citrate" or Xeljanz or CP690550 or Upadacitinib or "ABT-494" or RINVOQ or Cerdulatinib or "RVT-502" or PRT062070 or Peficitinib or ASP015K or Filgotinib or GLPG0634 or Solcitinib or "1206163-45-2" or GLPG0778 or GSK2586184 or SHR0302 or "ATI-502" or "ATI 50002" or "A 301" or "PF-06700841" or "RVT-501" or Decernotinib or "VX-509" or Pacritinib or SB1518 or Fedratinib or TG101348 or SAR302503 or "Fedratinib hydrochloride" or Inrebic).mp.

7	exp "Janus kinase inhibitor"/
8	(#1 OR #2) AND (#3 OR #4 OR #5)
9	(#1 OR #2) AND (#6 OR #7)


c. Search strategy for Cochrane Library

#	Search syntax
1	("atopic dermatitis" OR eczema*):ti,ab,kw
2	[mh "Dermatitis, Atopic "] OR [mh "Eczema"]
3	("venous thromboembolism" OR thromboemboli*):ti,ab,kw
4	[mh "Venous Thromboembolism "] OR [mh "Pulmonary Embolism"] OR [mh "Deep Vein Thrombosis"]
5	((Janus NEAR/2 kinase* NEAR/2 inhibit*) OR (JAK* NEAR/2 inhibit*) OR Abrocitinib OR "PF-04965842" OR Baricitinib OR LY3009104 OR Olumiant OR INCB028050 OR Gusacitinib OR ASN002 OR Tofacitinib OR Tasocitinib OR "Tofacitinib citrate" OR Xeljanz OR CP690550 OR Upadacitinib OR "ABT-494" OR RINVOQ OR Cerdulatinib OR "RVT-502" OR PRT062070 OR Peficitinib OR ASP015K OR Filgotinib OR GLPG0634 OR Solcitinib OR "1206163-45-2" OR GLPG0778 OR GSK2586184 OR SHR0302 OR "ATI-502" OR "ATI 50002" OR "A 301" OR "PF-06700841" OR "RVT-501" OR Decernotinib OR "VX-509" OR Pacritinib OR SB1518 OR Fedratinib OR TG101348 OR SAR302503 OR "Fedratinib hydrochloride" OR Inrebic):ti,ab,kw
6	[mh "Janus Kinase Inhibitors"]
7	(#1 OR #2) AND (#3 OR #4)
8	(#1 OR #2) AND (#3 OR #4) OR (#5 OR #6)

d. Search strategy for Web of Science Core Collection

#	Search syntax
1	ALL=("atopic dermatitis" OR eczema*)
2	ALL=("venous thromboembolism" OR thromboemboli*)
3	TS=(Abrocitinib OR "PF-04965842" OR Baricitinib OR LY3009104 OR Olumiant OR INCB028050 OR Gusacitinib OR ASN002 OR INCA24 OR Tofacitinib OR Tasocitinib OR "Tofacitinib citrate" OR Xeljanz OR CP690550 OR Upadacitinib OR "ABT-494" OR RINVOQ OR Cerdulatinib OR "RVT-502" OR PRT062070 OR Peficitinib OR ASP015K OR Filgotinib OR GLPG0634 OR Solcitinib OR "1206163-45-2" OR GLPG0778 OR GSK2586184 OR SHR0302 OR "ATI-502" OR "ATI 50002" OR "A 301" OR "PF-06700841" OR "RVT-501" OR Decernotinib OR "VX-509" OR Pacritinib OR SB1518 OR Fedratinib OR TG101348 OR SAR302503 OR "Fedratinib hydrochloride" OR Inrebic)
4	#1 AND #2
5	#1 AND #2 AND #3


1 eFigure 1. Risk Differences in Venous Thromboembolism Between
 2 Participants With Atopic Dermatitis Receiving Janus Kinase Inhibitors
 3 and Controls Receiving Placebo or Dupilumab



4

5 The meta-analysis found no significant difference in the risk of VTE between
 6 participants with atopic dermatitis receiving Janus kinase inhibitors and controls
 7 receiving placebo or dupilumab. CI, confidence interval; M-H, Mantel-Haenszel
 8 random-effects method.

9 **eFigure 2. Funnel Plot for Randomized Controlled Trials.** No funnel plot
10 asymmetry was indicated.



11

12 RD, risk difference; SE, standard error.